MRK · News · 20260821N

Melanoma Vaccine Collaboration

Merck & Co., Inc. · 2026-08-21 · Importance 59 · Surprise 60

Merck and Moderna reported positive Phase 3 results for intismeran, an individualized mRNA cancer vaccine, in patients with resected melanoma. The vaccine reduced melanoma recurrence when used with Merck’s Keytruda, strengthening Merck’s oncology pipeline and its potential replacement products ahead of Keytruda’s expected 2028 loss of exclusivity. Reports described the therapy as having multibillion-dollar commercial potential, although analysts cautioned that investor expectations may exceed its eventual therapeutic and sales impact.

Key facts

• Merck and Moderna announced positive Phase 3 trial results for an mRNA-based cancer vaccine developed in partnership with Moderna that demonstrated significant improvements in resected melanoma treatment. source
• An individualized cancer vaccine, intismeran, developed with Merck & Co., succeeded in a Phase 3 trial for melanoma. source